Therapy Areas: Central Nervous System
BioArctic developing new antibody treatment for ALS
15 November 2021 -

Swedish research-based biopharma company BioArctic AB (STO:BIOA B) said on Monday that its development project ND3014 is working on a potential new antibody treatment for the neurodegenerative disease ALS (amyotrophic lateral sclerosis).

Through this project, BioArctic aims to develop selective antibody treatments targeting TDP-43, a protein that is believed to play a crucial role in the development of ALS.

When TDP-43 (TAR DNA-binding protein 43) is misfolded it creates toxic aggregates, causing a stepwise degeneration of motor neurons in the brain, the brain stem and the spinal cord, BioArctic explained. Aggregates of TDP-43 in the central nervous system is a common clinical finding in ALS, found in most cases of patients in studies. Misfolded TDP-43 has also been shown in many patients with frontotemporal dementia and Alzheimer's disease.

The aim of BioArctic's development of selective antibody treatments toward TDP-43 is to decrease the levels of the toxic TDP-43 aggregates in nerve cells, and thus achieve a disease-modifying effect.

Login
Username:

Password:


Related Headlines